

PE/Dazzle™ 594 anti-mouse CD183 (CXCR3)

Catalog # / Size: 1379570 / 100 µg
1379565 / 25 µg

Clone: S18001A

Isotype: Rat IgG2b, κ

Immunogen: Mouse CXCR3-transfectants


Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide

Workshop Number: V-CD28.05

Concentration: 0.2 mg/mL




C57BL/6 splenocytes were stained with CD3ε FITC and CD183 (CXCR3) (clone S18001A) PE/Dazzle™ 594 (left) or rat IgG2b, κ PE/Dazzle™ 594 isotype control (right).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.



Bend.3 mouse endothelial cells were stained with CD63 (clone NVG-2) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).

* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.

Application Notes: Additional reported applications (for the relevant formats) include: Western blotting¹ and immunofluorescence¹.

Application References: 1. Verjan Garcia N, et al. 2011. *J. Immunol.* 187:2268. (WB, IF)

Description: CD183, also known as CXCR3, is a member of the C-X-C chemokine family, characterized by a pair of cysteine residues separated by a single amino acid. CXCR3 is a 38 kD seven pass transmembrane receptor coupled to G-protein. It mediates Ca²⁺ mobilization and chemotaxis in response to C-X-C chemokines, such as IP10 (CXCL10), MIG (CXCL9), I-TAC (CXCL11) and PF4 (CXCL4). CXCR3 is expressed primarily on activated T lymphocytes, NK cells, and some epithelial cells and endothelial cells. It is not expressed on B cells, monocytes, or granulocytes.

**Antigen
References:**

1. Farber JM. 1997. *J. Leukoc. Biol.* 61(3):\246-57.
2. Bonecchi R, *et al.* 1998. *J. Exp. Med.* 187(1):129-34.
3. Aota K, *et al.* 2018. *J. Oral. Pathol. Med.* 12756.
4. Kim B, *et al.* 2018. *Data. Brief.* 18:518-522.
5. Saahene RO, *et al.* 2018. *Cancer Biother. Radiopharm.* 2450.